Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology Association [Yahoo! Finance]
Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology Association
Keros Therapeutics, Inc. (NASDAQ: KROS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results [Yahoo! Finance]
Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results